Patient-reported outcomes in patients with relapsing forms of MS switching to teriflunomide from other disease-modifying therapies: Results from the global Phase 4 Teri-PRO study in routine clinical practice.
Sign Up to like & getrecommendations! Published in 2018 at "Multiple sclerosis and related disorders"
DOI: 10.1016/j.msard.2018.09.017
Abstract: BACKGROUND Patient-reported outcomes (PROs) can assist clinicians in understanding the impact of disease-modifying therapy (DMT) on the daily lives of patients with multiple sclerosis (MS). With an increased number of DMTs becoming available, patients are… read more here.
Keywords: satisfaction; week; clinical practice; treatment satisfaction ... See more keywords
Teriflunomide real-world evidence: Global differences in the phase 4 Teri-PRO study.
Sign Up to like & getrecommendations! Published in 2019 at "Multiple sclerosis and related disorders"
DOI: 10.1016/j.msard.2019.03.022
Abstract: BACKGROUND The demographics and management of patients with multiple sclerosis (MS) differ across geographical regions, but it is unclear whether/how these differences affect treatment outcomes. The aim of this post-hoc analysis was to assess teriflunomide… read more here.
Keywords: phase; real world; pro study; group ... See more keywords